| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Traditional Cytotoxic Agents
The primary biological target of AcLysValCit-PABC-DMAE-SW-163D is DNA. The payload, SW-163D, is a natural bis-intercalator that binds to DNA and interferes with DNA replication and transcription, leading to cell death. The linker, AcLysValCit-PABC-DMAE, is designed to be stable in circulation and to release the payload specifically within tumor cells, where specific proteases are overexpressed. This targeted delivery approach aims to maximize efficacy while minimizing systemic toxicity. |
|---|---|
| ln Vitro |
SW-163D is an antibiotic made of cyclodepsipeptides that was obtained from Streptomyces sp. Moreover, SW-163D demonstrates antitumor efficacy. PF06888667 is a strong, steady, and effective ADC made up of the bis-intercalator SW-163D conjugated to an engineered form of the anti-Her2 mAb, trastuzumab, catalyzed by transglutaminase, through a N-acetyl-lysine-valine-citrulline-p-aminobenzyl alcohol-N,N-dimethylethylenediamine (AcLysValCitPABC-DMAE) linker[1].
In vitro, AcLysValCit-PABC-DMAE-SW-163D is a drug-linker conjugate for ADCs. Its activity is dependent on its conjugation to a targeting antibody and subsequent internalization into target cells. The released payload, SW-163D, binds to DNA and induces cytotoxicity. The compound's antiproliferative activity is assessed using standard cell viability assays after conjugation to an appropriate antibody. The cleavage of the linker by proteases can be assessed using biochemical assays. |
| ln Vivo |
Information regarding the in vivo activity of AcLysValCit-PABC-DMAE-SW-163D in animal models is limited. Its biological activity is primarily characterized as part of an ADC. The in vivo efficacy of ADCs containing this drug-linker conjugate is assessed in xenograft models. The compound would be administered intravenously, and tumor growth would be monitored. Further studies are needed to determine its pharmacokinetic properties and efficacy in animal models.
|
| Enzyme Assay |
The non-cellular enzyme or receptor binding assay for AcLysValCit-PABC-DMAE-SW-163D involves measuring the cleavage of the linker by proteases such as cathepsin B. This can be performed using a biochemical assay with purified cathepsin B and the drug-linker conjugate. The cleavage products are analyzed by HPLC or LC-MS/MS. The stability of the linker in plasma can also be assessed by incubating it in plasma and measuring the release of the payload over time.
|
| Cell Assay |
The in vitro cellular assay for AcLysValCit-PABC-DMAE-SW-163D involves conjugating the drug-linker to a targeting antibody and then treating cancer cell lines with the resulting ADC. Cell viability is assessed using standard assays such as MTT or CellTiter-Glo to determine the IC50. The internalization of the ADC is assessed by immunofluorescence microscopy. The release of the payload within cells is assessed by measuring the levels of free SW-163D using LC-MS/MS.
|
| Animal Protocol |
The in vivo animal experiment workflow for AcLysValCit-PABC-DMAE-SW-163D involves the use of xenograft models in immunodeficient mice. Cancer cells expressing the target antigen are injected subcutaneously. Once tumors form, the ADC is administered intravenously at various doses. Tumor growth is monitored by measuring tumor volume. The concentration of the ADC and released payload in tumor tissue and plasma is measured using LC-MS/MS.
|
| References |
| Molecular Formula |
C85H113N19O22S2
|
|---|---|
| Molecular Weight |
1817.05
|
| Exact Mass |
1815.774
|
| CAS # |
2411007-69-5
|
| PubChem CID |
168012284
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.43±0.1 g/cm3(Predicted)
|
| LogP |
3.1
|
| tPSA |
604
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
27
|
| Rotatable Bond Count |
29
|
| Heavy Atom Count |
128
|
| Complexity |
4020
|
| Defined Atom Stereocenter Count |
14
|
| SMILES |
C[C@H]1C[C@]21C(OC[C@H](C(N[C@H](C(N([C@@H]1C(N([C@@]3(C(OC[C@H](C(N[C@H](C(N([C@@H]([C@@H](SC1)SC)C(N2C)=O)C)=O)C)=O)NC(C1=NC2C=CC=CC=2C=C1OC(=O)N(C)CCN(C)C(=O)OCC1C=CC(=CC=1)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)C)CCCCN)=O)=O)C[C@@H]3C)C)=O)C)=O)C)=O)NC(C1C(=CC2C=CC=CC=2N=1)O)=O)=O
|
| InChi Key |
VQIBTARTHBHUSL-LXZQIUEZSA-N
|
| InChi Code |
InChI=1S/C85H113N19O22S2/c1-44(2)63(98-68(108)56(91-49(7)105)26-19-20-32-86)71(111)95-57(27-21-33-88-81(87)120)67(107)92-53-30-28-50(29-31-53)40-125-82(121)99(8)34-35-100(9)83(122)126-62-37-52-23-16-18-25-55(52)94-65(62)73(113)97-59-42-123-79(118)84(38-45(84)3)103(12)76(116)60-43-128-78(127-14)66(102(11)75(115)48(6)90-70(59)110)77(117)104(13)85(39-46(85)4)80(119)124-41-58(69(109)89-47(5)74(114)101(60)10)96-72(112)64-61(106)36-51-22-15-17-24-54(51)93-64/h15-18,22-25,28-31,36-37,44-48,56-60,63,66,78,106H,19-21,26-27,32-35,38-43,86H2,1-14H3,(H,89,109)(H,90,110)(H,91,105)(H,92,107)(H,95,111)(H,96,112)(H,97,113)(H,98,108)(H3,87,88,120)/t45-,46-,47-,48-,56-,57-,58+,59+,60-,63-,66+,78+,84-,85-/m0/s1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5503 mL | 2.7517 mL | 5.5034 mL | |
| 5 mM | 0.1101 mL | 0.5503 mL | 1.1007 mL | |
| 10 mM | 0.0550 mL | 0.2752 mL | 0.5503 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.